bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977629; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. TGFβ Suppresses Type 2 Immunity to Cancer Ming Liu1, Fengshen Kuo2, Kristelle J. Capistrano1, Davina Kang1, Briana G. Nixon1,3, Wei Shi1, Chun Chou1, Mytrang H. Do1,3, Shun Li1, Efstathios G. Stamatiades1, Yingbei Chen4, James J. 3,5 3,6 7 2 1,3* Hsieh , A. Ari Hakimi , Ichiro Taniuchi , Timothy A. Chan , Ming O. Li 1Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA 10065 2Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center, New York, NY, USA 10065 3Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA 10065 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 10065 5Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, USA, 63110 6Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center New York, NY USA, 10065 7Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan 230-0045 * Correspondence:
[email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977629; this version posted March 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary The immune system employs two distinct defense strategies against infections: pathogen elimination typified by type 1 immunity, and pathogen containment exemplified by type 2 immunity in association with tissue repair.